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The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic
lymphocytic leukemia
Pablo Oppezzo, Yuri Vasconcelos, Catherine Settegrana, Dominique Jeannel, Franc¸oise Vuillier, Magali Legarff-Tavernier,
Eliza Yuriko Kimura, Ste´phane Bechet, Ge´rard Dumas, Martine Brissard, He´le`ne Merle-Be´ral, Mihoko Yamamoto,
Guillaume Dighiero, and Fre´de´ric Davi, for the French Cooperative Group on CLL
Although the zeta-associated protein of
70 kDa (ZAP-70) is overexpressed in pa-
tients with chronic lymphocytic leukemia
(CLL) displaying unmutated IGVH genes
and poor prognosis, a previous microar-
ray study from our group identified over-
expression of LPL and ADAM29 genes
among unmutated and mutated CLL, re-
spectively. To assess the prognostic value
of these genes, we quantified their expres-
sion by real-time quantitative polymerase
chain reaction (PCR) in a cohort of 127
patients with CLL and correlated this with
clinical outcome, IGVH mutational status,
and ZAP-70 protein expression. IGVH mu-
tational status, ZAP-70, and the LPL and
ADAM29 mRNA ratios (L/A ratio) were
predictive of event-free survival for the
whole cohort and for patients with stage
A disease. In patients in stage B and C,
the L/A ratio was an independent prognos-
tic factor, whereas ZAP-70 did not predict
survival. Simultaneous usage of the L/A
ratio and ZAP-70 expression allowed an
almost perfect (99%) assessment of the
IGVH status in the 80% of patients with
concordant results (L/A, ZAP-70 or
L/A, ZAP-70). LPL and ADAM29 gene
expression could also be determined by a
simple competitive multiplex reverse tran-
scription PCR assay. Overall, quantifica-
tion of LPL and ADAM29 gene expression
is a strong prognostic indicator in CLL,
providing better prognostic assessment
than ZAP-70 in advanced stages of the
disease. (Blood. 2005;106:650-657)
© 2005 by The American Society of Hematology
Introduction
Chronic lymphocytic leukemia (CLL) displays a variable outcome.
The classical Rai1 or Binet2 staging systems provided a basis for
therapeutic stratification by allocating CLL cases into 3 major risk
groups (low, intermediate, and high), according to tumor burden
and the presence of anemia and thrombocytopenia. Asymptomatic
patients with a low tumor burden (Binet stage A) do not benefit
from treatment with chlorambucil.3 However, the disease in half of
these patients will progress and both staging systems fail to initially
identify such patients. The advent of new treatments such as purine
analogues and monoclonal antibodies directed against CD20 and
CD52 are able to induce complete remissions and may allow early
treatment for asymptomatic patients whose disease is likely to
progress.3 Accurate identification of these patients is therefore
increasingly important.
Serologic markers such as lactic dehydrogenase, 2-microglobu-
lin,4 soluble CD23,5 and thymidine kinase4,6 are essentially indica-
tors of disease activity or tumor load or both, although some can
anticipate disease progression.7 Phenotypic expression of CD38
has been associated with aggressive disease,8 but the threshold
level for positive cases, if it exists at all, remains a matter of
debate.9-11 Genomic aberrations correlate well with either good
(isolated 13q) or poor (17p; 11q) prognosis in CLL,11,12
though their occurrence as a second malignant hit cannot be
definitely excluded. The mutational status of immunoglobulin
heavy chain variable (IGVH) genes has been considered as the best
prognostic marker in CLL.13 In an initial study, we observed that at
least half of CLL cases carried mutations using a cut-off of 98%
germline homology.14 This was further confirmed by others,15 some
of whom also correlated the IGVH mutational status to clinical
behavior.8,16,17 Mutated (MT) cases usually demonstrate a favor-
able evolution when compared to unmutated (UM) cases ( 98%
germline homology), which are characterized by progressive
disease, continuing treatment needs, and a high proportion of
CLL-related deaths.
Unexpectedly, recent reports indicated that ZAP70, normally ex-
pressed in T and natural killer (NK) lymphocytes, is also transcribed in
CLL B cells lacking IGVH mutations and is associated with poor
prognosis.18,19 Further series have confirmed these findings at the
protein level,20-23 suggesting a pivotal role for the zeta-associated protein
of 70 kDa (ZAP-70) in prognosis prediction in CLL.
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In a study of gene expression profiling performed on 18 CLL
cases, we identified a limited set of genes (n  85), which were
expressed differentially between progressive UM and stable MT
CLLs.24 We validated these results by real-time quantitative
polymerase chain reaction (RQ-PCR) for 18 genes on the same
cDNAs that were hybridized on the DNA chips. From these
RQ-PCR experiments, 4 genes in addition to ZAP70 appeared to
provide a better segregation of the 2 groups of CLL. These included
the lipoprotein lipase (LPL) and spartin (SPG20) genes, whose
expression was higher in UM cases, whereas disintegrin and
metalloproteinase 29 (ADAM29) and nuclear receptor-interacting
protein 1 (NRIP1) genes were found at higher levels in MT cases.
These findings led us to investigate, in an independent and larger
CLL series, whether these 4 genes (isolated or in combination)
could provide significant prognostic information and compared
their value with that of the IGVH mutational status and ZAP-70
protein expression.
Patients, materials, and methods
Patients and samples
This multicenter retrospective study was undertaken on samples from 127
patients whose diagnosis was made between October 1979 and February
2003, and identified from the registries of the Pasteur Institute and the
Pitie´-Salpeˆtrie`re hospitals, Paris, France (n  92), and the University
Hospital of Sa˜o Paulo, Brazil (n  35). Inclusion criteria consisted of: (1)
diagnosis of typical CLL based on morphologic and phenotypic analyses25;
(2) availability of frozen samples; (3) previous determination of IgVH
mutational status; and (4) patient’s informed consent according to French
and Brazilian regulations. Approval was obtained from the Pitie´-Salpeˆtrie`re
Hospital, the Pasteur Institute, and the University Hospital of Sa˜o Paulo for
these studies. This series included 87 patients with stage A, 29 with stage B,
and 11 with stage C disease. Median follow-up time was 73 months for the
whole series (range, 1-291 months), 87 months for patients in stage A and
50 months for patients in stages B and C. Progression was defined as change
of clinical stage or need for treatment or both.
All analyses were carried out on frozen peripheral blood samples. For
113 patients, samples had been taken at the time of diagnosis. In 14 stage A
cases with a very stable lymphocytosis over time, they were obtained at
distance from diagnosis. Mononuclear cells had been separated by Ficoll-
Hypaque gradient centrifugation and stored in liquid nitrogen. On thawing,
cell viability was first assessed by trypan blue exclusion and only samples
displaying more than 80% viability were further analyzed. In 5 cases,
leukemic B-cell populations were purified by negative magnetic selection
using anti-CD3, anti-CD14, anti-CD16, and anti-CD56 monoclonal antibod-
ies (Dynal, Oslo, Norway). Final purity was evaluated by flow cytometry to
be over 98%. Control samples from 20 healthy adult volunteers were
obtained using the same procedures and included peripheral mononuclear
blood cells (PBMCs, n  14) and purified peripheral blood B cells (n  6).
In addition the T-cell line Jurkat was cultured in RPMI 1640 medium
containing 10% fetal calf serum, 2 mM glutamine, 1% sodium pyruvate,
and penicillin-streptomycin.
IGVH mutational status
The IGVH gene sequences were determined as previously described.26
Briefly, amplification of immunoglobulin heavy chain variable regions by
PCR was performed on DNA from leukemic cells with consensus primers
for the VH framework region 1 and JH genes as previously described26 or
following the BIOMED-2 protocols.27 Purified PCR products were se-
quenced either directly or after a cloning procedure using an automated
DNA sequencer. Sequence data were analyzed using IgBLAST (http://
www.ncbi.nlm.nih.gov/igblast), the VBASE (http://vbase.mrc-cpe.cam.
ac.uk/), and the ImMunoGeneTics database (IMGT; http://imgt.cines.fr).
IGVH sequences were considered as mutated if their homology with the
closest germline counterpart was less than 98%.
RNA isolation and cDNA synthesis
Total cellular RNA was extracted using the RNeasy kit (Qiagen, Courta-
boeuf, France) following the supplier’s instructions. The integrity of RNA
was assessed by visualization of the 18S and 28S RNA species on
electrophoresis in agarose gel after ethidium bromide staining. First-strand
cDNA was synthesized from 2 g total RNA, using Superscript II reverse
transcriptase (RT; Invitrogen, Cergy-Pontoise, France) and oligodT or
random hexamer primers.
Quantitative RT-PCR
For gene expression analyses of LPL, SPG20, ADAM29, and NRIP1, we
performed RQ-PCR using the Light Cycler System (Roche Molecular
Biochemicals, Mannheim, Germany) and the SYBR Green I dye. Primers
used in this study (Table 1) were designed with the GeneRunner software
(Hastings Software, Hastings, NY). RQ-PCRs were carried out on 100 ng
reverse transcribed total RNA (cDNA) with the following parameters: 10
minutes at 95°C for initial denaturation, then 40 cycles of 10 seconds at
95°C, 5 seconds at 62°C, and 17 seconds at 72°C. The specificity of the
amplified products was verified by analysis of their respective melting
curves as provided by the Light Cycler software. All reactions were done in
duplicate and each PCR run also included the 5 points of the calibration
curve and a no template control. Estimation of the quality of cDNA for each
sample was done by quantification of an endogenous reference, the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The gene copy
number was calculated with a standard curve generated from serially
diluted (10-fold dilutions from 106 to 102 copies) plasmids containing the
respective sequence-verified insert. Results were expressed as the ratio of
mean of gene copy number/mean GAPDH copy number 100.
Multiplex RT-PCR
We also evaluated the relative expression of LPL and ADAM29 by
multiplex RT-PCR, using the same primers than those for RQ-PCR (Table
1). Different concentrations of primers, MgCl2, and deoxyribonucleoside
triphosphate (dNTP) were first evaluated. Optimized PCR conditions were
obtained with primers at the final concentrations of 0.5 M for LPL and
0.25 M for ADAM29, 1.5 mM MgCl2, and 200 M dNTP. Amplifications
were performed on 100 ng cDNA and included an initial denaturation step
at 94°C for 5 minutes, followed by 29 cycles of 30 seconds at 95°C, 20
seconds at 62°C, and 30 seconds at 72°C. Finally, the reaction was
completed with a final elongation step at 72°C for 5 minutes. PCR products
were analyzed on 2% agarose gel electrophoresis stained with ethidium
bromide, where they appeared as a 445–base pair (bp) band for ADAM29
and a 410-bp band for LPL. Amplification of GAPDH was performed in
parallel to ensure cDNA integrity.
Multiparametric flow cytometry
Flow cytometric analysis of ZAP-70 intracellular expression was per-
formed using the method described by Crespo et al20 with some minor
Table 1. Sequences of primers used in RQ-PCR and multiplex PCR
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modifications. Thawed mononuclear cells were fixed in 2% paraformalde-
hyde and were then permeabilized by incubation with phosphate-buffered
saline containing 0.1% saponin (Sigma, Saint-Quentin Favallier, France)
and 0.5% bovine serum albumin. One million cells were first incubated with
2.5 g anti–ZAP-70 antibody (clone 2F3.2; Upstate Biotechnology, Lake
Placid, NY) or irrelevant isotype-matched anti-CD14 monoclonal antibod-
ies (Dako Cytomation, Trappes, France). After washing, they were incu-
bated with 1.5 g F(ab)2 fluorescein isothiocyanate (FITC)–conjugated
goat antimouse antibody (Immunotech, Marseille, France). Cells were then
washed and incubated with phycoerythrin-cyanin 5 (PC5)–conjugated
mouse anti-CD19 (Immunotech), allophycocyanin (APC)–conjugated mouse
anti-CD3, and APC-conjugated mouse anti-CD56 (BD Biosciences, San
Jose, CA). Samples including at least 104 cells were further analyzed with a
flow cytometer (FACSCalibur; BD Biosciences) and the use of Cell Quest
Pro software (BD Biosciences). Lymphocyte cells were first selected on
size structure characteristics and then gated on B cells (CD19) and T and
NK cells (CD3CD56). Bi-parametric dot-plot graphs were obtained
separately for cells that were stained for, respectively, CD3, CD56, and
ZAP-70, or CD19 and ZAP-70, or CD3, CD56, and CD14 (negative
control). In those plots as well as in mono-parametric histograms, ZAP-70
expression on CD3CD56 cells served to determine the percentage of
CLL cells that were positive for ZAP-70.
Statistical analyses
Expression levels of the 4 tested genes and of ZAP-70 protein were
compared with the IGVH mutational status as a reference. Threshold values
that could best discriminate MT from UM cases were first determined by
plotting expression values against IGVH percentage of germline homology,
and then further refined by calculating the Youden index28 and validity
index (the percentage of correctly classified cases). Thereafter, the perfor-
mance indexes including sensitivity, specificity, and positive and negative
predictive values were determined. Distributions of patients, according to
Binet staging, sex, and IgVH mutational status were compared using 	2 test.
Median follow-up periods were calculated for each Binet stage group.
Because CLL-related deaths were mainly observed in stages B and C (only
4 cases in stage A), whereas disease progression was the most frequent
event for patients in stage A, we evaluated event-free survival (EFS), from
diagnosis to date of disease progression or CLL-related death or last
follow-up visit, for the whole cohort and patients in stage A. Overall
survival was calculated only for patients in stage B and C. Survival analyses
were performed using the Kaplan-Meier method. Statistical significance of
associations between individual variables and survival was calculated by
the log-rank test. Univariate and multivariate regression analyses were done
according to the Cox proportional hazards regression model. Because the
biologic factors studied as prognostic indicators were strongly correlated
with IGVH mutational status, it was inappropriate to test them simulta-
neously by Cox regression. Consequently, 2 Cox regression analyses were
performed, with the first one testing IGVH mutational status, and the second
one testing the other selected factors, in both circumstances with adjustment
for age, sex, and when appropriate the Binet staging. Variables with 2-tailed
P values of less than .05 were considered to be significant. All analyses
were done using SPSS Statistical Software, version 11.5 (SPSS, Chicago, IL).
Results
Patient characteristics
Table 2 summarizes the characteristics of the 127 patients. Eighty-
seven patients were in stage A, 29 in stage B, and 11 in stage C.
Twenty disease-related deaths were recorded and 4 additional
deaths, unrelated to CLL, occurred among patients in stage A.
Fifty-three patients (42%) were allocated to the UM IGVH group,
whereas 74 displayed a MT IGVH profile. The MT and UM cases
were heterogeneously distributed within Binet stages because 69%
of patients in stage A displayed a MT IGVH profile, whereas 65%
were UM among B and C cases (P 
 .001). Sex distribution was
also heterogeneous with a high proportion of male patients among
UM cases (70%) and a slight female predominance (53%) in the
MT group (P  .05). Based on French Cooperative Group guide-
lines, almost all patients with stage B and C disease received early
treatment, whereas treatment was deferred for those with stage A
disease until disease progression. This was the case for 22 patients
(25%) in stage A, 4 of whom died.
Selection of LPL and ADAM29 as potential prognostic
markers in CLL
Because our microarray study showed that LPL and SPG20 were
overexpressed among UM CLLs, whereas ADAM29 and NRIP1
predominated in MT CLLs, we first evaluated expression of these 4
Table 2. Clinical and biologic characteristics of patients
Stage A Stage B Stage C Stages BC Stages ABC
No. of patients 87 29 11 40 127
Age, y* 63.0 58.0 59.0 58.5 61.0
Male sex, no. (%) 51 (59) 24 (83) 5 (45) 29 (72) 80 (63)
Lymphocyte count, 109/L* 15.2 37.2 151.8 45.0 19.0
Hemoglobin level, g/dL* 14.1 13.4 7.2 13.0 13.8
Platelet count, 109/L* 212.5 160.0 187.5 172.0 198.0
Lymphocyte doubling time, no (%)
More than 12 mo 64 (84) NA NA NA NA
Less than 12 mo 12 (16) NA NA NA NA
IGVH genes, no (%)
UM 27 (31) 17 (59) 9 (82) 26 (65) 53 (42)
MT 60 (69) 12 (41) 2 (18) 14 (35) 74 (58)
ZAP-70, no (%)
Less than 20% 45 (65) 7 (30) 3 (33) 10 (31) 55 (54)
20% or greater 24 (35) 16 (70) 6 (67) 22 (69) 46 (46)
L/A ratio, no (%)
Less than 1 56 (69) 13 (46) 2 (20) 15 (39) 71 (60)
1 or greater 25 (31) 15 (54) 8 (80) 23 (61) 48 (40)
Progression, no (%) 22 (25) NA NA NA NA
CLL-related death, no (%) 4 (5) 10 (34) 6 (55) 16 (40) 20 (18)
NA indicates not applicable.
*Median values
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genes in an initial series of 71 patients. Quantification was
performed on total lymphocytes because preliminary experiments
in 5 patients showed similar results when compared to purified
leukemic cells (data not shown). For each gene, we determined
which expression levels could best segregate UM from MT cases
using the Youden and validity indexes. Results showed that overall
LPL and ADAM29 performed better than SPG20 and NRIP1 to
predict UM and MT IGVH profiles, respectively (Tables 3 and 4).
The concordance rate was 80% for ADAM29, 77% for LPL, 65%
for SPG20, and 55% for NRIP1. Next, we investigated whether a
combination of the most discriminating parameters by a simple 1:1
LPL/ADAM29 (L/A) ratio could improve their individual perfor-
mance. With a calculated threshold of 1, the L/A ratio displayed
better sensitivity and specificity than each marker taken individu-
ally. Positive predictive value (PPV) was 91% for UM cases and
negative predictive value (NPV) was 86% for MT patients,
providing a better performance than each individual marker (Tables
3 and 4). Thus the L/A ratio constituted the best marker reflecting
the mutational status of IGVH genes in this cohort of 71 patients
with CLL, with a concordance rate of 89%.
Reproducibility of LPL and ADAM29 quantification
Next, we tested the reproducibility of LPL and ADAM29 quantifica-
tion by RQ-PCR. This was done by comparing results obtained
from replicate samples for 4 patients, 2 overexpressing LPL and 2
overexpressing ADAM29. For each patient, 4 replicates were
analyzed during the same reaction run (intrarun variability), and
this was repeated on 3 different days (interrun variability). The
overall variability of these 12 replicates is shown in Table 5. Of
note, intrarun variability was always smaller than overall variabil-
ity, with the coefficient of variation (CV) being less than 0.5% for
LPL and less than 1.1% for ADAM29 (data not shown).
The L/A ratio is a strong predictor of prognosis in CLL
We evaluated the prognostic value of the L/A ratio in an extended
cohort of 127 patients. This included the 71 initially studied
patients and 56 additional cases selected because of their prolonged
follow-up and the availability of frozen samples. In addition we
compared its value to that of the mutational profile of IGVH genes
and ZAP-70 protein expression. LPL and ADAM29 were available
for 119 patients, whereas ZAP-70 could be determined for 101
patients and all 3 parameters for 93 patients. On this larger series,
the L/A ratio once again provided a better concordance (90%) with
IGVH mutational status than LPL (76%) or ADAM29 (82%) taken
individually (data not shown), and threshold values were found to
be identical to those of the first cohort (Figure 1). ZAP-70
expression was measured by flow cytometry in leukemic B cells in
comparison with that of the patients’ T and NK cells. A cutoff value
at 20% of cell positivity was found to provide the best correlation
with IGVH genes (Figure 1).
Median EFS for the entire cohort was 87 months in CLLs
displaying UM IGVH genes as compared to 149 months in MT
patients (P 
 .001). It was 84 months for patients with an L/A ratio
above 1 and 88 months for patients expressing ZAP-70, whereas
median EFS was not achieved for those with an L/A ratio below 1
(P 
 .001) or ZAP-70 (P 
 .001; Figure 2A). Multivariate Cox
regression showed that, with adjustment for age and sex, UM IGVH
and stage B or C were independently associated with disease
progression or CLL-related death with hazard ratios of, respec-
tively, 5.0 (P 
 .001) and 2.6 (P  .01; Table 6). Similarly, an L/A
ratio above 1 and stage B or C were independently and significantly
associated with shorter EFS. ZAP-70, however, was not found to be
an independent prognosis factor.
In patients with stage A disease, an identical median EFS of 87
months was observed for patients with UM IGVH genes, an L/A
ratio above 1, and expressing ZAP-70, whereas it was not achieved
for cases with MT IGVH genes, an L/A ratio below 1, and ZAP-70
(all P 
 .001; Figure 2B). In multivariate Cox analyses, after
adjustment for age and sex, both ZAP-70 and L/A ratio were
independent significant prognostic factors. This was also true for
the IGVH mutational status (Table 6).
The 40 patients in stage B and C were analyzed together for
evaluation of overall survival (OS; Figure 2C). There was a trend
for longer OS in patients with MT than in those with UM IGVH
genes (128 versus 79 months; P  .067). The L/A ratio was
predictive of survival because patients with a ratio above 1 had a
median OS of 79 months, whereas it was not yet reached at time of
analysis for those with a ratio below 1 (P  .03). In contrast,
ZAP-70 did not correlate with survival in this group (100 versus 80
months; P  .28). By multivariate Cox analysis, an L/A ratio
below 1 was found as a significant prognostic factor, whereas
ZAP-70 was not independently associated with survival. In a
separate Cox analysis, IGVH mutational status became a significant
prognosis factor, after adjustment for age and sex (Table 6).
Table 4. Parameters calculated in relation to unmutated IGVH genes
for LPL, SPG20, and LPL/ADAM29 and to mutated IGVH genes for
ADAM29 and NRIP1
LPL ADAM29 SPG20 NRIP1 LPL/ADAM29
Sensitivity, % 81 82 54 56 86
Specificity, % 74 78 76 54 91
PPV, % 77 78 71 53 91
NPV, % 78 83 60 57 86
Table 5. Reproducibility of RQ-PCR
Patient
LPL ADAM29
Ct  SD CV, % Ct  SD CV, %
CLL-73 23.54  0.46 1.97 NA NA
CLL-105 23.96  0.38 1.59 NA NA
CLL-67 NA NA 27.33  1.18 4.31
CLL-101 NA NA 23.32 2.21
Overall variability of RQ-PCR quantification of LPL and ADAM29 gene expres-
sion was evaluated on 12 replicates performed on 4 different CLL patients. This was
done by testing each sample in 4 replicates during the same reaction (intrarun
variability), this being repeated on 3 different days (interrun variability).
Ct indicates threshold cycle; SD, standard deviation; CV, coefficient of variation;
NA, not applicable.
Table 3. Correlation of gene expression with IGVH mutational status
LPL ADAM29 SPG20 NRIP1 LPL/ADAM29
1 or more Less than 1 3 or more Less than 3 3.5 or more Less than 3.5 4 or more Less than 4 1 or more Less than 1
UM, n 37 30 7 8 29 20 17 17 20 32 5
MT, n 34 9 25 28 6 8 26 19 15 3 31
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Correlation between L/A ratio, ZAP-70 expression, and IGVH
mutational status
Given the strong prognostic value of the 3 markers, we next
assessed the correlation between them in the 93 cases for whom all
3 parameters had been determined. Cases were scored as “positive”
or “negative” for a given marker based on expression values above
or below the thresholds. Concordance rate with IGVH mutational
status was 85% for ZAP-70, thus slightly lower than that obtained
with the L/A ratio (92%; Table 7). As depicted in Table 7, all
double-positive patients (ZAP-70L/A; n  30) except one ex-
pressed UM IGVH genes, and all double-negative patients (ZAP-
70L/A; n  44) had MT IGVH genes. Although an almost
perfect correlation for all 3 markers was found for these cases (73
of 74, 99% accuracy), discordant profiles still accounted for
20% of CLL patients. They included 13 patients expressing a
ZAP-70L/A profile, whereas 6 patients were ZAP-70L/A.
Among the 13 ZAP-70L/A cases, 4 had UM IGVH genes (1
stage A and 3 stage B), whereas 9 had MT IGVH genes (7 stage
A and 2 stage B). Four of the 6 patients with a ZAP-70L/A
profile displayed UM IGVH genes (3 stage A and 1 stage C),
whereas they were MT in the remaining 2 cases (1 stage A and 1
stage B). Of note, the mutational status of these 19 discordant
cases would have been predicted correctly more often by the
L/A ratio alone (13 cases) than by ZAP-70 expression alone (6
cases). The small number of patients with discordant markers
did not allow prognostic evaluation.
Determination of the LPL and ADAM29 gene expression by a
simple qualitative multiplex RT-PCR assay
To simplify the assessment of LPL and ADAM29 gene expression,
we developed a multiplex RT-PCR assay, where both genes were
simultaneously amplified generating PCR products of different
size, respectively, 410 bp and 445 bp (Figure 3). This assay was
then evaluated on 95 patients of our series. Experiments were done
in duplicate on separate PCRs for 25 cases and showed a perfect
reproducibility. Using our defined PCR conditions, the results were
unambiguous in 89 cases with production of a single band or 2
bands but with one clearly more intense than the other. They
correlated with the RQ-PCR results because 34 of the 36 patients
with an L/A ratio above 1.0 expressed predominantly LPL in the
multiplex assay, whereas 2 displayed products of both size with
roughly similar intensities (doublets). Alternatively, 55 of the 59
patients exhibiting a L/A ratio less than 1.0 expressed predomi-
nantly ADAM29, whereas 4 displayed doublets (Table 8). Thus,
inconclusive results (doublets) were observed for 6 patients. In 5 of
these 6 cases, the L/A ratio values were in the range of 0.7 to 1.5.
There was, therefore, a very good concordance between the results
Figure 2. Kaplan-Meier survival curves in CLL according to IGVH
mutational status, L/A ratio, or ZAP-70 expression. (A) EFS
probabilities for the total population. (B) EFS probabilities for patients
in stage A. (C) OS probabilities for patients with stages B and C
disease.
Figure 1. Correlations between LPL/ADAM29 ratio or ZAP-70 expression and
the IgVH gene mutational status. The threshold values calculated for the L/A ratio
(  1) and ZAP-70 (  20%) showing the best concordance rate with the IGVH
mutational status, as determined by using the Youden index, are indicated by a
horizontal line.
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obtained by RQ-PCR and qualitative multiplex PCR. Prognostic
evaluation performed with LPL and ADAM29 gene expression
determined by multiplex PCR produced identical results to those
obtained by RQ-PCR (data not shown).
Expression of LPL and ADAM29 genes in normal
circulating cells
Although experiments on purified and unpurified CLL cells showed
similar results, we wanted to evaluate a possible expression of LPL
and ADAM29 genes in normal cells, which might contaminate
patient samples. For this, we assessed their expression by multiplex
PCR in the peripheral blood cells of 20 healthy individuals. Very
low level of expression of LPL was found in 3 of the 14 PBMCs
tested and in 1 of the 6 purified B-cell samples. ADAM29 was not
detected in any of the PBMCs and at a very low level in one of the
purified B-cell samples. In addition the T-cell line Jurkat failed to
express either of these 2 genes. Thus, all or most of the LPL and
ADAM29 transcripts that we measured in patient samples origi-
nated from leukemic cells and not from background normal
mononuclear cells.
Discussion
The recent development of microarray technology has allowed the
discovery of genes, which may have prognostic significance in
human tumors. A previous gene expression profiling study in CLL
led us to identify a set of genes that appeared to segregate stable
MT from progressive UM forms.24 In the present work, we show
that the combined expression of 2 of them, LPL and ADAM29,
constitutes a new prognostic marker in CLL.
LPL is a heparin-releasable enzyme bound to glycosaminogly-
can components of the capillary endothelium and is particularly
abundant in muscle, adipose tissue, and macrophages. With
apolipoprotein CII, LPL mediates the hydrolysis of triacylglycerol
component of circulating chylomicrons and very-low-density li-
poproteins. It plays a central role in lipid metabolism and trans-
port.29,30 Mutations in the LPL gene are frequently associated with
dyslipidemia and atherosclerosis.29,31 In line with our findings on
normal cells, other investigators have failed to detect LPL expres-
sion in normal purified B and T lymphocytes.32 However, they
found that it was expressed and secreted by NK cells, where it was
shown to modulate their cytotoxic activity. Reasons for its high
expression in UM CLL B cells are unknown. Because UM CLL B
cells have been shown to be more responsive to stimulation through
their antigen receptor,33,34 we speculate that LPL could play a role
in lipid raft formation or stabilization, a biologic process known to
be important in B-cell activation.35 The ADAM29 gene encodes a
member of the disintegrin and metalloproteinase family of trans-
membrane proteins, which have been shown to mediate cell-to-cell
or cell-to-matrix interactions (or both) as well as the proteolytic
shedding of cell surface molecules.36,37 In contrast to other ADAMs
that are expressed in various tissues, ADAM29 transcripts are
highly restricted to the testis.38,39 Because its precise functions are
Figure 3. Multiplex PCR determination of LPL and ADAM29 expression. LPL and
ADAM29 transcripts were amplified simultaneously; the PCR products were then
separated by electrophoresis on agarose gel and visualized under UV illumination
after ethidium bromide staining. Amplification of the GAPDH gene from the same
transcripts served as control of cDNA integrity. MWM indicates molecular weight
marker; MT, mutated; UM, unmutated; B, purified B cells from a healthy individual; T,
Jurkat T-cell line.
Table 7. Groups of CLL patients according to L/A ratio and
ZAP-70 expression
ZAP-70L/A ZAP-70L/A ZAP-70L/A ZAP-70L/A
UM 29 4 4 0
MT 1 9 2 44
Total, no. (%) 30 (32) 13 (14) 6 (6) 44 (47)
Positivity or negativity for ZAP-70 refers to expression values 20% or 
20%,
respectively. Positivity or negativity for L/A ratio refers to expression values  1
or 
1, respectively.






greater than 1 Total
ADAM29 55 0 55
LPL 0 34 34
Doublet 4 2 6
Total 59 36 95
Cases were scored as ADAM29 or LPL according to the type of the predominant
PCR product obtained by multiplex RT-PCR. When 2 bands of roughly similar
intensity were observed, they were qualified as doublet.
Table 6. Prognostic factors for disease progression and
CLL-related death in multivariate Cox regression
Factor Hazard ratio (95% CI) P
All stages, EFS for all stages
Model 1 including IGVH
Age 1.1 (1.0-1.2) .20*
Sex, male 1.4 (1.0-2.0) .29
Binet stage B/C 2.6 (1.8-3.7) .01
UM IGVH 5.0 (3.4-7.2) 
.001
Model 2 including L/A ratio†
Age 1.1 (1.0-1.2) .50*
Sex, male 1.4 (1.2-2.7) .12
Binet stage B/C 2.5 (1.7-3.7) .02
L/A ratio 1 or greater 5.6 (3.8-8.1) 
.001
EFS for Binet stage A
Model 1including IGVH
Age 1.0 (0.9-1.1) .86*
Sex, male 1.6 (1.0-2.3) .28
UM IGVH 5.7 (3.6-9.1) 
.001
Model 2 including L/A ratio
and ZAP-70
Age 0.9 (0.8-1.0) .29*
Sex, male 1.7 (1.0-2.7) .32
ZAP-70 greater than 20% 4.2 (2.3-7.7) .02
L/A ratio 1 or greater 3.9 (2.1-7.2) .03
OS for stages B and C
Model 1 including IGVH
Age 1.5 (1.2-1.8) .03*
Sex, male 1.0 (0.5-2.1) .99
UM IGVH 7.2 (3.4-15.1) .01
Model 2 including L/A ratio†
Age 1.6 (1.3-2.0) .05*
Sex, male 0.5 (0.3-1.3) .46
L/A ratio 1 or greater 6.8 (3.3-14) .01
Multivariate analyses were done separately for IGVH or ZAP-70 and L/A ratio due
to the high concordance between the latter 2 parameters and the former.
*P for trend test.
†ZAP-70 was not independently associated with disease progression or CLL-
related death and was then eliminated in the final Cox model.
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so far unknown, its role in the biology of CLL remains unex-
plained. The fact that for these 2 genes: (1) similar results were
obtained on total CLL lymphocyte populations and from purified
leukemic cells, and (2) their absence of detection or very low level
in normal peripheral B cells, indicates that their overexpression
could be tumor specific. Alternatively, it might reflect a restricted
expression in a minor B-lymphoid subpopulation, which is ex-
panded in CLL. Further experiments on purified B-cell subsets are
warranted to prove whether these hypotheses are correct.
The discovery that ZAP70 gene expression could differentiate
MT from UM CLLs has also emerged from microarray experi-
ments.18,19 Further studies confirmed its presence at the protein
level by flow cytometry and showed that it had prognostic
impact.20-23 We evaluated the ability of the L/A ratio as well as
ZAP-70 expression and the IGVH mutational status to predict
clinical outcome in our cohort of patients with CLL. In univariate
analysis, all 3 parameters correlated with EFS in the whole
population. In multivariate analysis, however, ZAP-70 was no
longer selected. For stage A patients, these 3 biologic parameters
were predictive of EFS. When considering the patients with stage B
and C disease, the L/A ratio was the only parameter that correlated
significantly with survival in univariate analysis. The IGVH UM
status became a significant risk factor only after adjustment for sex
and age in multivariate analysis. Rassenti et al reported recently
that ZAP-70 was a better predictor of time from diagnosis to initial
therapy than the IGVH mutational status.23 The lack of information
concerning the patients’ clinical stage in this cohort makes
comparison with our data difficult. In our study, most of patients in
stages B and C received early treatment, whereas it was delayed in
those with stage A disease until progression was observed.
Therefore, only patients in stage A can be compared. As noted,
ZAP-70, the L/A ratio, and the IGVH mutational status were all
similarly capable of predicting treatment-free survival for this
group of patients. In contrast, ZAP-70 expression had no prognos-
tic value in patients in stages B and C. Similar findings have also
been reported by Crespo et al.20 It remains to be elucidated why
ZAP-70, which is a strong prognostic parameter for patients in
stage A, does not predict outcome for patients in stages B and C.
The availability of biologic prognostic indicators such as the L/A
ratio for stage B and C CLL cases may therefore be of great
importance for future risk-adapted treatments. For the cases with
discordant results for ZAP-70, L/A ratio, and IGVH genes, it was
unclear which of these 3 biologic parameters was the most reliable
prognostic indicator. Larger series will be necessary to determine
which most accurately predict clinical evolution.
In the present study, we also evaluated the correlations between
these 3 biologic prognostic markers. The concordance rate with
IGVH mutational status was slightly higher for the L/A ratio (92%)
than for ZAP-70 (85%). For this latter parameter, the threshold
value that best correlated with the IGVH mutational status was
found to be 20%, similar to that previously described by Crespo et
al20 and Rassenti et al,23 but higher than that used by Orchard et al22
(10%). The discordance rate with the IGVH status was slightly
higher than that observed by Crespo et al20 and Orchard et al22
(respectively, 5.4% and 7.8%) but lower than that of Rassenti et al
(23%). In this latter work, the investigators used another anti-
ZAP-70 antibody and a different gating strategy.23 These discor-
dant results might be due to technologic reasons, in addition to the
type of patients studied. Further studies evaluating the different
technologic aspects of its detection are clearly needed before
ZAP-70 expression can be used in a clinical perspective. Interest-
ingly, concordant results for ZAP-70, L/A ratio, and IGVH genes
were found in about 80% of cases. Provided that these results are
confirmed in larger series of patients, combining ZAP-70 and L/A
ratio quantification may represent an alternative to sequencing the
IGVH genes in about 80% of patients.
We also describe an alternative method to assess simultaneous
expression of LPL and ADAM29 by a multiplex competitive
RT-PCR technique. Although it was not informative in a minority
of cases, in our hands this assay proved to be simple and
reproducible. Its extension to a routine test, however, requires
further evaluation by independent laboratories. The determination
of the IGVH mutational status is an expensive labor-intensive
technique not well suited as a routine test in most clinical
laboratories. Simpler techniques such as flow cytometric quantifica-
tion of ZAP-70 or PCR-based expression analysis of LPL and
ADAM29 genes represent promising alternatives. Standardization
of these techniques, as well as evaluation of their cost, including
comparison of RQ-PCR and multiplex RT-PCR for LPL and
ADAM29, will be important for future therapeutic protocols. A cost
comparison evaluation of the different techniques to assess progno-
sis in stage A CLL is currently being performed in France.
In summary, our study shows that LPL and ADAM29 constitute
new and strong prognosis markers in CLL. Importantly, they
provide better prognostic information than ZAP-70 for advanced
CLL cases. In addition, combination of the L/A ratio with ZAP-70
expression predicts accurately the IGVH mutational status in 80%
of CLL cases, thus rendering sequencing unnecessary in these
patients.
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